↓ Skip to main content

Dove Medical Press

Article Metrics

Lebrikizumab in the personalized management of asthma

Overview of attention for article published in Biologics: Targets & Therapy, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#21 of 224)
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
6 tweeters
patent
10 patents
facebook
2 Facebook pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
48 Mendeley
Title
Lebrikizumab in the personalized management of asthma
Published in
Biologics: Targets & Therapy, September 2012
DOI 10.2147/btt.s28666
Pubmed ID
Authors

Neil Thomson, Manish Patel, Smith

Abstract

There is a need for improved therapies for severe asthma. Lebrikizumab, a humanized monoclonal antibody that binds to interleukin (IL)-13, is under development for the treatment of poorly controlled asthma. This article reviews the potential role of IL-13 in the pathogenesis of asthma, the efficacy and safety of lebrikizumab in humans, and progress in patient selection for lebrikizumab therapy. IL-13 is a T-helper (Th2) cell-derived cytokine implicated in inflammatory responses in asthma, including serum immunoglobulin-E synthesis, mucus hypersecretion, and subepithelial fibrosis. Blocking the pro-inflammatory effects of IL-13 with lebrikizumab has the potential to improve asthma control. Published data on the efficacy and safety of lebrikizumab in the treatment of asthma are relatively limited. The late asthmatic response after inhaled allergen challenge is reduced by almost 50%, following treatment with lebrikizumab. In a Phase II study performed in 219 adults with poorly controlled asthma despite inhaled corticosteroids (MILLY trial), lebrikizumab produced an improvement in prebronchodilator forced expiratory volume in 1 second of 5.5% compared with placebo at 12 weeks, but had no effects on other efficacy end points. Adverse effects were similar to placebo, except that musculoskeletal side effects occurred slightly more often with lebrikizumab. Stratifying patients into a high Th2 phenotype using serum periostin, which is upregulated in lung epithelial cells by IL-13, may identify individuals responsive to blockade of IL-13. In the MILLY trial, lebrikizumab treatment was associated with greater improvement in lung function in patients with elevated serum periostin levels compared with those with low periostin levels. Two large Phase III randomized controlled trials in patients with uncontrolled asthma are underway to establish the safety and efficacy of lebrikizumab when administered over a 52-week period. These studies will also help to determine whether identifying patients with a Th2 high inflammatory phenotype using serum periostin allows a personalized approach to the treatment of asthma.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 2%
Unknown 47 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 25%
Other 8 17%
Student > Master 7 15%
Student > Ph. D. Student 5 10%
Professor > Associate Professor 3 6%
Other 6 13%
Unknown 7 15%
Readers by discipline Count As %
Medicine and Dentistry 20 42%
Agricultural and Biological Sciences 5 10%
Biochemistry, Genetics and Molecular Biology 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Immunology and Microbiology 2 4%
Other 4 8%
Unknown 11 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2020.
All research outputs
#2,462,531
of 17,601,811 outputs
Outputs from Biologics: Targets & Therapy
#21
of 224 outputs
Outputs of similar age
#18,516
of 140,086 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 7 outputs
Altmetric has tracked 17,601,811 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 224 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 140,086 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.